Precision medicine uses information about differences between people to make healthcare decisions more specific. Genomics can contribute to that process by helping explain a condition, identify a relevant biological pathway, or clarify how someone may respond to a medicine. Its value depends on the question being asked and the evidence connecting a result to an appropriate decision. More DNA data does not automatically produce clarity.
The useful promise of precision medicine is better informed care for particular situations. Understanding that promise also means recognizing what remains essential: clinical assessment, a person's circumstances, reliable evidence, and room for uncertainty.
Where genomics fits within precision medicine
Precision medicine considers genetic differences alongside environmental and lifestyle factors. The MedlinePlus explanation of precision medicine describes an approach aimed at understanding which prevention or treatment strategies are likely to work for which groups of people.
Genomic medicine is the use of genomic information as part of clinical care. It overlaps with precision medicine, but the broader approach can also use information beyond DNA. Measurements of proteins, details in a medical history, and other characteristics may be relevant to a specific question.
The word “personalized” sometimes creates the impression that every patient receives a medicine invented uniquely for them. In many applications, the aim is to identify a subgroup for whom an existing approach has stronger evidence. The individual decision still takes place within knowledge gathered from other people.
Our overview of human genome testing explains the testing side of that process, including why the scope of a test should fit its purpose.
Three settings where genetic information can matter
Investigating a suspected genetic condition
In a diagnostic setting, a clinician may use genetic testing to investigate an explanation suggested by symptoms, examination, or family history. A result may help confirm a particular condition or guide further investigation. It may also leave the question unresolved.
For example, a family may seek an explanation for a pattern of symptoms. Finding a relevant variant is only part of the work: the clinical team must assess whether the finding fits the person's presentation and whether the evidence supports that interpretation. The name of a gene alone is not a complete explanation.
Understanding response to medicines
Pharmacogenomics examines how genetic variation relates to drug response. Some variants affect processes involved in how a medicine is handled by the body; others can be relevant to particular adverse reactions. For some gene–drug relationships, evidence can inform clinical decisions.
The FDA emphasizes that genetic makeup is one of several factors affecting drug concentrations and response. Evidence that a variant changes metabolism is also different from evidence that testing for it improves patient outcomes. A pharmacogenomic report therefore belongs in a discussion with the prescribing clinician, together with the person's other medicines and clinical circumstances.
Characterizing a cancer
Cancer biomarker testing can look for genetic changes, proteins, or other features that help inform treatment discussions. Some findings can suggest that a treatment is more likely to help, while others offer no useful treatment information.
A match between a biomarker and a therapy is not a guarantee of benefit. A tumor can contain cells with different features, and its characteristics can change over time. These limitations help explain why a molecular report is one input into cancer care and why the circumstances of the sample matter.
Inherited findings and tumor findings have different meanings
A change found in a tumor is not automatically an inherited change. Genetic alterations can arise in cells during a person's lifetime. Inherited variants, by contrast, can be passed through egg or sperm cells and may have implications for relatives.
The distinction changes the question a result can answer. A test describing a tumor may help characterize that cancer without establishing a family's inherited risk. A finding that raises an inherited-risk question may require a separate clinical assessment or confirmatory testing.
When reading a report, ask what material was analyzed and what the report claims to establish. “Genetic” describes the type of information involved; it does not, on its own, tell you whether that information was inherited or whether relatives should draw conclusions from it.
Measurement, interpretation, and usefulness are separate
A test can measure a DNA variant accurately without establishing that the variant explains a symptom or that acting on the result improves care. Three concepts help keep these questions clear:
- Analytical validity: how reliably the test detects the genetic change it is designed to measure.
- Clinical validity: how well that change is associated with the condition or outcome being considered.
- Clinical utility: whether the information is useful for diagnosis, prevention, or management.
Consider a hypothetical report that identifies a variant associated with a biological pathway. Before the result could support a clinical decision, there would need to be evidence about its meaning in that setting and about the proposed action. The existence of a plausible mechanism is not the final step.
This is why an impressive number of tested variants is an incomplete measure of value. Ask which decision the test is designed to inform, what evidence supports that use, and how the answer would change the next conversation about care.
More precise information can still be uncertain
Some findings have well-established interpretations; others are reported as variants of uncertain significance because the available evidence does not settle their relationship to disease. Uncertainty is a description of the evidence, not a diagnosis waiting to be assumed.
A negative result also needs its scope stated. It may mean that no relevant change was found among the regions and variant types the test could assess. It does not necessarily exclude every genetic explanation. Our guide to genetic test results explores positive, negative, and uncertain findings in context.
Interpretations can change as research develops. Ask whether reassessment is offered, who would receive an updated interpretation, and whether you need to maintain contact with the original clinical service. Do not assume that a laboratory or portal will automatically revisit every historical result indefinitely.
Genetic risk is not an individual forecast
For many conditions, health outcomes reflect combinations of genetic influences, exposures, and other circumstances. A genomic result can change an estimate of risk without fixing a person's future. Family history and clinical information still contribute to the interpretation.
A numerical example makes this easier to see. If a hypothetical risk changes from five in one hundred to six in one hundred over the same time period, that is a 20 percent relative increase and an absolute increase of one percentage point. Neither number tells us which individual will experience the outcome.
Whenever a report uses terms such as “higher risk,” ask higher than what, over which time period, and in which population. Also ask how the estimate combines with information already known about the person. These questions turn an alarming or reassuring label into something that can be evaluated.
Ask whose evidence supports the result
Research participants do not represent every population equally. A model developed using one set of participants needs evaluation before its performance is assumed to transfer to everyone else. This is particularly relevant to polygenic risk scores, which combine information from many variants. NHGRI's PRIMED program was designed to improve methods and applicability across diverse populations.
Ask whether evidence exists for people with relevant ancestry and clinical characteristics, and whether the report explains remaining limits. A broad racial label is an incomplete description of a person's genetic background or circumstances.
Our guide to human genome databases explains why the source, composition, and purpose of a dataset matter when assessing information built from it.
Research participation and clinical care need clear expectations
Research aims to generate knowledge. Clinical testing aims to answer questions relevant to an individual's care. A research study may not return individual results, and receiving research information does not necessarily mean it is ready for clinical use.
Before participating, ask about the study's purpose, whether individual findings will be returned, and how samples and data may be reused. Costs and practical access also matter: an informative result is only one part of a pathway that includes explanation and any relevant follow-up.
Our genetic counseling guide explains how a genetics professional can help people consider possible results, family implications, and personal priorities. Useful preparation includes asking: What might this test clarify? What could remain uncertain? Who will help interpret the result? What happens next for each possible outcome?
Focus on the decision the evidence can support
Precision medicine adds information that can make some healthcare decisions more specific. It does not remove the need to understand the person, evaluate evidence, or acknowledge limits. A useful genomic test has a clear purpose, an appropriate interpretation, and a plan for discussing the result. Those features help distinguish a meaningful contribution to care from an interesting finding whose practical role remains unresolved.
